Prostate Cancer Drug Linked to Lower Risk of Cognitive Decline

Prostate Cancer Drug Linked to Lower Risk of Cognitive Decline

CHICAGO — Patients with advanced prostate cancer treated with enzalutamide (Xtandi) had a significantly greater decline in cognitive function compared with those who received darolutamide (Nubeqa), according to results from a phase II trial. Median cognitive change in the maximally changed cognitive domain (MCCD) from baseline to 24 weeks was -15.8% for those receiving darolutamide…

Read More

Ebola treatment center set alight in Congo

IE 11 is not supported. For an optimal experience visit our site on another browser. Now Playing Ebola treatment center set alight in Congo 00:44 UP NEXT Anthony Joshua, boxer who defeated Jake Paul, survives deadly car crash 01:18 Department of Defense video shows a missile being launched after Nigeria strikes 00:15 Livestream captures gunmen…

Read More